TECX vs UTHR
TECX: A clinical-stage biotechnology company developing GPCR-targeted biologic medicines for diseases with significant unmet medical needs. UTHR: United Therapeutics is a biotechnology company dedicated to providing innovative, life-extending therapies for patients with pulmonary arterial hypertension and other rare diseases through a focus on proprietary treprostinil-based treatments.
Side-by-side fundamentals
| Metric | TECX | UTHR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $22.75 | $532.78 | |
| Market cap | $445M | $22.9B | |
| P/E as of 2026-10-08 | n/a | 19.06 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.83 | |
| Net margin FY2025, SEC XBRL | n/a | +41.9% | |
| Gross margin FY2025, SEC XBRL | n/a | +87.9% | |
| Operating margin FY2025, SEC XBRL | n/a | +46.9% | |
| ROE FY2025, SEC XBRL | -29.5% | +18.8% | UTHR higher |
| ROA FY2025, SEC XBRL | -28.4% | +16.9% | UTHR higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | UTHR lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +2.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.59 | 0.39 | |
| 1-year return as of 2026-10-08 close | +48.1% | +18.7% | TECX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.